Loading clinical trials...
Loading clinical trials...
A Phase 1, 4-Part, Open-Label, Randomized Study With A 5-Period, 4 Sequence, Crossover Design to Compare the Single Dose Pharmacokinetics Between Immediate and Modified Release Formulations of Danuglipron Administered Orally to Healthy Adult Participants
Conditions
Interventions
Danuglipron
Locations
1
United States
Anaheim Clinical Trials, LLC
Anaheim, California, United States
Start Date
November 27, 2023
Primary Completion Date
September 30, 2024
Completion Date
September 30, 2024
Last Updated
October 21, 2024
NCT07310901
NCT06342713
NCT06014515
NCT07401472
NCT07412353
NCT07280858
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions